Litigation Details for Medicis Pharmaceutical Corporation v. Nycomed US Inc. (S.D.N.Y. 2011)

« Back to Dashboard

Medicis Pharmaceutical Corporation v. Nycomed US Inc. (S.D.N.Y. 2011)

Docket	1:11-cv-04551	Date Filed	2011-07-05
Court	District Court, S.D. New York	Date Terminated	2011-08-16
Cause	35:271 Patent Infringement	Assigned To	Denise Cote
Jury Demand	None	Referred To
Patents	6,765,001; 7,220,424; 7,794,738
Link to Docket	External link to docket

Details for Medicis Pharmaceutical Corporation v. Nycomed US Inc. (S.D.N.Y. 2011)

Date Filed	Document No.	Description	Snippet	Link To Document
2011-07-05				External link to document

Medicis Pharmaceutical Corporation v. Nycomed US Inc. | 1:11-cv-04551 Litigation Summary

Last updated: October 9, 2026

Medicis Pharmaceutical Corporation filed a Hatch-Waxman patent-infringement action against Nycomed US Inc. in the U.S. District Court for the Southern District of New York under Case No. 1:11-cv-04551. The dispute arose from Nycomed's abbreviated new drug application for a generic version of a Medicis dermatology product. The public record identifies the case as an ANDA litigation matter, but the available docket information does not establish a reported merits judgment, a publicly accessible claim-construction opinion, or a disclosed settlement term.

What was Medicis Pharmaceutical Corporation v. Nycomed US Inc. about?

The case was a pharmaceutical patent dispute triggered by Nycomed's ANDA filing. Medicis alleged that Nycomed's proposed generic product would infringe patents listed for the relevant reference-listed drug. The case therefore followed the standard Hatch-Waxman structure:

1. Nycomed filed an ANDA with a Paragraph IV certification.
2. Medicis sued within the statutory 45-day period.
3. The filing imposed an automatic 30-month stay on FDA approval, subject to statutory exceptions.
4. The parties litigated whether the proposed generic product infringed Medicis' listed patents and whether the asserted claims were valid and enforceable.

The docket number is 1:11-cv-04551 in the Southern District of New York. The plaintiff was Medicis Pharmaceutical Corporation; Nycomed US Inc. was the ANDA filer and defendant.

Which drug and patents were involved?

The case concerned a Medicis dermatology product, but the accessible case-identification data does not reliably establish the product name or the complete patent list associated with Nycomed's ANDA. A definitive product, patent-number, dosage-form, and expiration-date attribution cannot be made from the docket caption alone.

This matters because Medicis maintained patent estates covering multiple dermatology products, including:

• extended-release minocycline products;
• low-dose doxycycline products;
• topical dermatology formulations;
• acne-treatment methods;
• rosacea-treatment methods; and
• product-specific dosage forms and release profiles.

The relevant patent claims in a Hatch-Waxman case can cover the active ingredient, composition, release characteristics, dosing regimen, treatment method, or manufacturing process. The case caption does not identify which of those categories was asserted.

What was the procedural posture of the case?

Item	Publicly identifiable information
Case	Medicis Pharmaceutical Corporation v. Nycomed US Inc.
Court	U.S. District Court for the Southern District of New York
Civil action	1:11-cv-04551
Filing year	2011
Case type	Hatch-Waxman patent infringement
Plaintiff	Medicis Pharmaceutical Corporation
Defendant	Nycomed US Inc.
Trigger	ANDA filing and Paragraph IV certification
Regulatory consequence	Statutory FDA approval stay likely applied
Reported merits decision	No reliably identifiable published merits opinion
Public settlement terms	Not established from the case caption and docket metadata

The litigation was regulatory-driven rather than a conventional commercial patent dispute. Medicis' primary objective was to delay or prevent FDA approval of Nycomed's ANDA until expiration of the asserted patents or resolution of the litigation.

How did the Paragraph IV challenge affect FDA approval?

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. When the brand company files an infringement action within 45 days, FDA approval is generally stayed for 30 months under the Hatch-Waxman statute. The stay can terminate earlier if the court enters judgment for the ANDA applicant or otherwise resolves the statutory conditions for approval.

The case therefore created three principal regulatory outcomes:

• Medicis could obtain a judgment blocking approval until patent expiration.
• Nycomed could prevail on invalidity, noninfringement, or unenforceability and pursue earlier approval.
• The parties could settle and establish a contractually defined launch date, subject to antitrust and regulatory constraints.

A 30-month stay should not be treated as proof that Medicis' patents were valid or infringed. The stay is a procedural consequence of the filing of the action.

What patent litigation affected the commercial launch?

The commercial effect depended on the identity of the reference product and the asserted patents. If the case was resolved by settlement, the principal commercial term would have been Nycomed's permitted generic launch date. Such agreements commonly address:

• an early-entry date;
• a license to the relevant patents;
• supply arrangements;
• authorized-generic restrictions;
• launch conditions tied to patent invalidation or earlier third-party entry; and
• allocation of litigation costs.

No reliable public source in the available case-identification record establishes the existence or terms of a settlement agreement. It is therefore not possible to assign an authorized launch date or quantify the settlement's effect on Medicis' exclusivity.

Was there a final judgment on infringement or validity?

No published final merits decision can be reliably attributed to Case No. 1:11-cv-04551 from the available information. There is no confirmed basis to state that:

• Nycomed's ANDA product was found to infringe;
• the asserted Medicis patents were upheld;
• the patents were invalidated;
• the patents were held unenforceable; or
• FDA approval was permanently barred.

The absence of a reported merits opinion is commercially relevant. It indicates that the public case record does not provide a judicial test of the asserted patent claims. Patent-strength analysis must therefore rely on the underlying patents, prosecution history, Orange Book listings, claim scope, and any confidential settlement terms rather than on a litigated validity holding.

What was the Orange Book status?

The Orange Book status cannot be determined from the civil docket alone. Orange Book analysis requires matching:

1. the Medicis reference-listed drug;
2. its active ingredient and dosage form;
3. the patents listed by FDA;
4. the use codes for method-of-use patents;
5. the ANDA number filed by Nycomed; and
6. the timing and type of Nycomed's certification.

The litigation caption does not identify those fields. A reliable Orange Book conclusion cannot therefore be drawn about:

• which patents were listed;
• whether the patents were composition, formulation, method-of-use, or process patents;
• whether FDA removed or delisted any patent;
• whether the ANDA carried Paragraph IV, Paragraph III, or Section viii certifications; or
• whether Nycomed obtained first-filer status.

How strong was the Medicis patent estate?

The case alone does not establish patent strength. A business assessment would distinguish between claim categories:

Formulation patents

Formulation claims can provide meaningful protection when they cover a commercially important release profile, particle-size distribution, excipient combination, or dosage form that a generic cannot easily design around. Their strength depends on claim construction and whether the ANDA formulation practices every limitation.

Method-of-use patents

Method claims can remain commercially relevant when the FDA-approved indication is narrow and the label requires the patented use. Their practical value falls when the generic can use a Section viii statement and omit the patented indication from its label.

Active-ingredient or composition claims

These claims generally provide the broadest protection but are vulnerable to prior-art and written-description challenges. Their remaining term is also decisive.

Manufacturing patents

Manufacturing claims can create technical barriers, but they usually impose less direct launch risk unless the ANDA process necessarily practices the asserted claims or the patent owner can obtain meaningful discovery into the generic's manufacturing process.

Without identified patent numbers and claim language, the Medicis estate cannot be rated as strong, moderate, or weak on the basis of this docket alone.

Which companies were challenging Medicis products?

Nycomed was the ANDA challenger in this case. Medicis also faced generic competition across its dermatology portfolio from other companies in separate proceedings. Those cases should not be conflated with 1:11-cv-04551 because each ANDA may involve different products, certifications, patents, settlement dates, and launch rights.

The relevant competitive landscape would include:

• Nycomed's proposed generic;
• other ANDA applicants for the same reference product;
• authorized-generic suppliers;
• branded alternatives in acne and rosacea;
• competing topical products; and
• other extended-release tetracycline products, if the case involved a tetracycline brand.

What generic-entry risks existed for Medicis?

The case created four principal risks:

1. Patent invalidity risk. A successful Paragraph IV challenge could remove the principal barrier to entry.
2. Noninfringement risk. Nycomed could design around formulation or method claims.
3. Settlement risk. An agreed early-entry date could shorten the expected exclusivity period.
4. Label risk. A generic could omit a patented indication and enter under a Section viii statement.

The commercial exposure would have been highest if the challenged product had concentrated revenue, limited therapeutic substitution, and few remaining patents. Exposure would have been lower if Medicis had unasserted formulation patents, multiple approved indications, or a strong branded prescriber base.

Did the case create biosimilar risk?

No. The dispute was an ANDA-based generic-drug case, not a biologics-license application or biosimilar proceeding under the Public Health Service Act. Biosimilar concepts such as interchangeability, the Purple Book, patent dance procedures, and reference-product exclusivity do not apply to this case.

What is the current litigation significance?

The case is primarily relevant as evidence that Medicis actively enforced its pharmaceutical patent portfolio against ANDA challengers in 2011. It does not, based on the available public record, establish a precedential ruling on claim construction, obviousness, written description, enablement, inequitable conduct, or Hatch-Waxman litigation procedure.

For transaction, licensing, or investment analysis, the case should be treated as a historical enforcement event rather than as a confirmed patent-validity win for Medicis or a confirmed generic launch win for Nycomed.

Key Takeaways

• Medicis Pharmaceutical Corporation sued Nycomed US Inc. in the Southern District of New York under Case No. 1:11-cv-04551.
• The case was a Hatch-Waxman ANDA and Paragraph IV patent dispute.
• The docket caption does not reliably identify the reference product, asserted patent numbers, expiration dates, or use codes.
• No confirmed published merits judgment can be attributed to the case from the available record.
• The case does not establish that Medicis' patents were upheld, invalidated, infringed, or held unenforceable.
• The 30-month FDA stay, if triggered by the filing, was procedural and did not determine patent validity.
• The proceeding involved generic-drug risk, not biosimilar risk.
• Any analysis of launch timing, Orange Book coverage, revenue exposure, or settlement economics requires product- and patent-level records beyond the case caption.

FAQs

What court heard Medicis v. Nycomed?

The case was filed in the U.S. District Court for the Southern District of New York under Civil Action No. 1:11-cv-04551.

Was Nycomed a generic-drug applicant?

Yes. The litigation arose from Nycomed's ANDA filing and Paragraph IV challenge to Medicis patent rights.

Did Medicis win the case?

A confirmed published merits judgment cannot be established from the available case-identification record.

Did Nycomed launch a generic product?

The case record identified here does not establish a generic launch date or commercial launch.

Is Medicis v. Nycomed relevant to biosimilar litigation?

No. It was an ANDA-based small-molecule generic case, not a biosimilar proceeding.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals. https://www.fda.gov/drugs
3. U.S. Congress. (2024). 21 U.S.C. § 355: New drugs. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section355
4. U.S. Courts. (2024). PACER case locator. https://pcl.uscourts.gov
5. Medicis Pharmaceutical Corporation v. Nycomed US Inc., No. 1:11-cv-04551, U.S. District Court for the Southern District of New York (2011).